- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Ursula A. Matulonis, MD | Authors
Ursula A. Matulonis, MD, Talks Future of Mirvetuximab Soravtansine in Ovarian Cancer
November 27, 2022
Ursula A. Matulonis, MD, spoke about the next steps for mirvetuximab soravtansine in the treatment of patients with folate receptor α–high platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, Reviews Additional Trials Investigating Mirvetuximab Soravtansine in FR-α–Positive Platinum-Resistant Ovarian Cancer
November 22, 2022
Ursula A. Matulonis, MD, discussued studies are being conducted assessing the use of mirvetuximab soravtansine in patients with folate receptor-α–positive platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, Highlights How Mirvetuximab Soravtansine FDA Approval in FR-α+ Platinum-Resistant Ovarian Cancer Could Impact Treatment
November 16, 2022
Ursula A. Matulonis, MD, indicated that acknowledgement of external targets such as FR-α could lead to success with antibody-drug conjugates in platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, on the Approval of Mirvetuximab Soravtansine in FR-α–Positive Platinum-Resistant Ovarian Cancer
November 15, 2022
Ursula A. Matulonis, MD, spoke about the phase 3 SORAYA trial and how it helped lead to the approval of mirvetuximab soravtansine in folate receptor-α–positive platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, Discusses the Toxicity Profile of Mirvetuximab Soravtansine in Advanced Ovarian Cancer With High FR- α Expression
October 26, 2022
At 2022 IGCS, Ursula A. Matulonis, MD, spoke about the toxicity profile observed with mirvetuximab soravtansine monotherapy in patients with folate receptor α–high platinum-resistant ovarian cancer reported from the phase 3 SORAYA study.
Ursula A. Matulonis, MD, Reviews Efficacy of Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer With High FR- α Expression
October 22, 2022
Ursula A. Matulonis, MD, spoke about the updated results of the phase 3 SORAYA trial with mirvetuximab soravtansine in patients with folate receptor α–high platinum-resistant ovarian cancer presented at 2022 IGCS.
Ursula A. Matulonis, MD, Reviews the Rationale Behind the SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer With High FR-α Expression
October 12, 2022
Ursula A. Matulonis, MD, spoke about the motivation behind the phase 3 SORAYA trial investigating mirvetuximab soravtansine in patients with folate receptor α–high platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, on Future Focus With Mirvetuximab Soravtansine in Ovarian Cancer
April 28, 2022
Ursula A. Matulonis, MD, speaks to potential future uses of mirvetuximab soravtansine in ovarian cancer.
Ursula A. Matulonis, MD, on the Safety of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
April 22, 2022
In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.
Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
April 14, 2022
Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.